<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="more than 185,000 fatalities as of April 23, 2020. Coronavirus" exact="disease" post="2019 (COVID-19) causes a respiratory illness with symptoms such"/>
 <result pre="of April 23, 2020. Coronavirus disease 2019 (COVID-19) causes a" exact="respiratory" post="illness with symptoms such as dry cough, fever, sudden"/>
 <result pre="is no specific vaccine or treatment proven effective against this" exact="viral" post="disease. Early and accurate diagnosis of COVID-19 is thus"/>
 <result pre="polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), clustered regularly interspaced" exact="short" post="palindromic repeats (CRISPR), and microfluidics, have allowed better disease"/>
 <result pre="interspaced short palindromic repeats (CRISPR), and microfluidics, have allowed better" exact="disease" post="diagnosis. Here, as part of the effort to expand"/>
 <result pre="COVID-19 and discuss ongoing clinical trials of interventions to reduce" exact="viral" post="progression. Funding National Natural Science Foundation of China21771135 National"/>
 <result pre="sixth public health emergency of international concern, following H1N1 (2009)," exact="Polio" post="(2014), Ebola in West Africa (2014), Zika (2016), and"/>
 <result pre="expansion and rising fatalities have raised grave concerns on the" exact="viral" post="spread across the globe. With the rapid increase in"/>
 <result pre="COVID-19 can spread from person-to-person and animal, and transmission of" exact="infection" post="may occur with exposure to symptomatic patients or asymptomatic"/>
 <result pre="animal, and transmission of infection may occur with exposure to" exact="symptomatic" post="patients or asymptomatic individuals. Coronaviruses (CoVs) (corona: crown-like shape)"/>
 <result pre="The first two Î²-CoVs (HCoV-OC43 and HCoV-HKU1) mainly cause self-limiting" exact="upper" post="respiratory infections, while the other two Î²-CoVs (SARS-CoV and"/>
 <result pre="first two Î²-CoVs (HCoV-OC43 and HCoV-HKU1) mainly cause self-limiting upper" exact="respiratory" post="infections, while the other two Î²-CoVs (SARS-CoV and MERS-CoV)"/>
 <result pre="two Î²-CoVs (SARS-CoV and MERS-CoV) are mostly associated with severe" exact="respiratory" post="illness [6, 7]. Full-genome sequence analysis of 2019-nCoV confirms"/>
 <result pre="replication, while structural proteins are responsible for virion assembly and" exact="viral infection" post="[12, 13]. The M and E proteins are required"/>
 <result pre="while structural proteins are responsible for virion assembly and viral" exact="infection" post="[12, 13]. The M and E proteins are required"/>
 <result pre="[12, 13]. The M and E proteins are required in" exact="viral" post="assembly, while the N protein involves RNA genome assembly."/>
 <result pre="S protein, a surface-located trimeric glycoprotein of CoVs, is the" exact="primary" post="determinant of CoV tropism, as it binds to the"/>
 <result pre="it binds to the membrane receptor on host cells, mediating" exact="viral" post="and cellular membrane fusion [14]. The S protein of"/>
 <result pre="receptor for binding of the 2019-nCoV S protein, thereby mediating" exact="viral" post="invasion [18]. The E protein is an integral membrane"/>
 <result pre="The E protein is an integral membrane protein that regulates" exact="viral" post="life cycles, including pathogenesis, envelope formation, assembly, and budding"/>
 <result pre="of developing protein E-derived peptides as a 2019-nCoV vaccine [22]." exact="Systemic" post="studies of proteins S and E have inspired scientists"/>
 <result pre="of breath, sore throat, and headache. In some severe cases," exact="infections" post="can cause pneumonia, severe acute respiratory syndrome, kidney failure,"/>
 <result pre="headache. In some severe cases, infections can cause pneumonia, severe" exact="acute" post="respiratory syndrome, kidney failure, and death. According to the"/>
 <result pre="In some severe cases, infections can cause pneumonia, severe acute" exact="respiratory" post="syndrome, kidney failure, and death. According to the WHO-China"/>
 <result pre="severe cases, infections can cause pneumonia, severe acute respiratory syndrome," exact="kidney failure," post="and death. According to the WHO-China joint report [23],"/>
 <result pre="report [23], on average, people infected with 2019-nCoV develop mild" exact="respiratory" post="symptoms and fever, 5-6 days after infection (mean incubation"/>
 <result pre="2019-nCoV develop mild respiratory symptoms and fever, 5-6 days after" exact="infection" post="(mean incubation period, 5-6 days; range, 1-14 days). People"/>
 <result pre="60 years of age and those with hypertension, diabetes, or" exact="cardiovascular" post="diseases are at high risk for severe illness and"/>
 <result pre="of all reported cases). Based on the Chinese Center for" exact="Disease" post="Control and Prevention (China CDC) report (from 72,314 patient"/>
 <result pre="and biomarkers that hosts exhibit after infection. These biomarkers include" exact="viral" post="proteins and nucleic acids, as well as antibodies induced"/>
 <result pre="nucleic acids, as well as antibodies induced in response to" exact="viral infection." post="The most common 2019-nCoV detection methods include viral nucleic"/>
 <result pre="to viral infection. The most common 2019-nCoV detection methods include" exact="viral" post="nucleic acid detection and serum antibody (IgG or IgM)"/>
 <result pre="result for 2019-nCoV nucleic acid, using real-time PCR tests from" exact="respiratory" post="or blood samples; (ii) a high homogeneity between viral"/>
 <result pre="from respiratory or blood samples; (ii) a high homogeneity between" exact="viral" post="gene sequencing from respiratory or blood samples and known"/>
 <result pre="samples; (ii) a high homogeneity between viral gene sequencing from" exact="respiratory" post="or blood samples and known 2019-nCoV; and (iii) serum"/>
 <result pre="titer to 2019-nCoV in the recovery phase than in the" exact="acute" post="phase [25]. 2.1. Nucleic Acid Targeting 2.1.1. High-Throughput Sequencing"/>
 <result pre="has been widely applied in genome sequencing, transcriptional profiling (RNA-seq)" exact="disease" post="mapping, and population genetic studies. The whole-genome nucleotide sequence"/>
 <result pre="with higher sensitivity (100-fold) than standard qPCR, simultaneously with other" exact="respiratory" post="viruses within 6-10â€‰h. Moreover, all targeted regions can be"/>
 <result pre="nucleic acids extracted from 2019-nCoV specimens qualitatively. Positive results indicate" exact="infection" post="with 2019-nCoV. RT-PCR is an advanced technique for coronavirus"/>
 <result pre="and probe-target regions in the 2019-nCoV genome [32]; second, low" exact="viral" post="load present in test specimens, improper extraction of nucleic"/>
 <result pre="TMA assays, input RNA is converted to a double-stranded DNA" exact="intermediate" post="with a promoter region. Detection of RNA using DNA"/>
 <result pre="require thermal or chemical melting with the aid of enzymes." exact="Combined" post="with a visual detection platform, such as a lateral"/>
 <result pre="chemical melting with the aid of enzymes. Combined with a" exact="visual" post="detection platform, such as a lateral flow assay (LFA)"/>
 <result pre="organic dyes, LAMP and RPA have been widely employed in" exact="viral" post="detection kits. LAMP is a rapid, one-step amplification technique"/>
 <result pre="widely adopted to detect animal and human pathogens, such as" exact="hand, foot, and mouth disease" post="(HFMD) virus, human immunodeficiency virus (HIV), bovine coronavirus, or"/>
 <result pre="animal and human pathogens, such as hand, foot, and mouth" exact="disease" post="(HFMD) virus, human immunodeficiency virus (HIV), bovine coronavirus, or"/>
 <result pre="such as hand, foot, and mouth disease (HFMD) virus, human" exact="immunodeficiency" post="virus (HIV), bovine coronavirus, or MERS-CoV [49â€&quot;52]. Currently, RPA"/>
 <result pre="specific vs. 90% specific for qRT-PCR) detection of 2019-nCoV in" exact="respiratory" post="swab samples. Realistically, CRISPR/Cas-based 2019-nCoV detection technology is highly"/>
 <result pre="abovementioned methods are based on relative quantification, because they require" exact="external" post="calibration with genetic standards or inner reference DNA templates,"/>
 <result pre="widely utilized in various fields, including drug screening, tissue engineering," exact="disease" post="diagnostics, and nucleic acid detection [66, 67]. Based on"/>
 <result pre="to detect several kinds of genes with parallel sample panels." exact="Digital" post="PCR can also be conducted with droplets generated by"/>
 <result pre="even femtoliter), leading to unacceptable errors. Using airtight devices or" exact="high pressure" post="delays liquid evaporation but complicates the devices and increases"/>
 <result pre="liquid evaporation but complicates the devices and increases testing costs." exact="Digital" post="LAMP is more compatible with microfluidics than digital PCR"/>
 <result pre="further validated with real clinical samples. 2.2. Target Antigen and" exact="Antibody" post="As mentioned above, the primary diagnostic methods are virological"/>
 <result pre="samples. 2.2. Target Antigen and Antibody As mentioned above, the" exact="primary" post="diagnostic methods are virological detection involving viral nucleic acids."/>
 <result pre="mentioned above, the primary diagnostic methods are virological detection involving" exact="viral" post="nucleic acids. Another approach to detection is with serological"/>
 <result pre="in the host after recovery. It could be merely a" exact="short" post="time frame for detection. As such, serological tests should"/>
 <result pre="diagnosis. 2.2.1. Enzyme-Linked Immunosorbent Assay (ELISA) Early diagnosis of 2019-nCoV" exact="infection" post="is of utmost importance both for medical teams to"/>
 <result pre="to manage patients effectively and for policymakers to curb the" exact="viral" post="spread. Presently, ELISA in cell culture extracts has proven"/>
 <result pre="family [79]. In a bold, novel approach, a team of" exact="infectious disease" post="experts in Singapore utilized an ELISA against 2019-nCoV to"/>
 <result pre="[79]. In a bold, novel approach, a team of infectious" exact="disease" post="experts in Singapore utilized an ELISA against 2019-nCoV to"/>
 <result pre="verified that a couple allegedly infected with COVID-19 had the" exact="disease" post="because they had exceedingly elevated levels of virus-specific antibodies"/>
 <result pre="couple had recovered from the 2019-nCoV infection, they had no" exact="viral" post="genetic materials in their bodies, but the antibodies persisted."/>
 <result pre="were also other reports of using ELISA to diagnose 2019-nCoV" exact="infection" post="[81, 82]. Each study confirmed the high reproducibility and"/>
 <result pre="established that the presence of immunoglobulin M (IgM) indicates a" exact="primary" post="defense against viral infections. This IgM defense occurs before"/>
 <result pre="presence of immunoglobulin M (IgM) indicates a primary defense against" exact="viral" post="infections. This IgM defense occurs before the production of"/>
 <result pre="and IgG antibodies may provide epidemiologists with crucial information on" exact="viral infection" post="of test subjects, allowing them to adjust policies to"/>
 <result pre="IgG antibodies may provide epidemiologists with crucial information on viral" exact="infection" post="of test subjects, allowing them to adjust policies to"/>
 <result pre="used to complement RT-PCR and antibody-antigen serological testing. These include" exact="chest" post="computed tomography (CT) and transmission electron microscopy (TEM). Each"/>
 <result pre="imaging tools are indispensable and form an essential component of" exact="viral" post="diagnosis, as well as for monitoring viral progression [85]."/>
 <result pre="essential component of viral diagnosis, as well as for monitoring" exact="viral" post="progression [85]. They have also been used for follow-up"/>
 <result pre="also been used for follow-up in outpatient settings for coronavirus-related" exact="pulmonary" post="disorders. Just like both SARS and MERS, pulmonary complications"/>
 <result pre="for coronavirus-related pulmonary disorders. Just like both SARS and MERS," exact="pulmonary" post="complications in COVID-19 patients have been observed. Learning from"/>
 <result pre="well-documented SARS and MERS studies, CT imaging results in the" exact="acute" post="and chronic periods of COVID-19 are invariant, but not"/>
 <result pre="and MERS studies, CT imaging results in the acute and" exact="chronic" post="periods of COVID-19 are invariant, but not always present"/>
 <result pre="These features include bilateral, multifocal, ground glass opacities, with a" exact="peripheral" post="distribution (Figure 7(a)) [93]. Crucially, more than half of"/>
 <result pre="study presented multilobar involvement and lesions more prominently in the" exact="lower" post="lobes of their lungs. Given its feasibility and ease"/>
 <result pre="use, CT has become an essential tool for the 2019-nCoV" exact="infection" post="diagnosis. From a radiological perspective, the advantages of using"/>
 <result pre="had a profound impact on our understanding of illnesses, including" exact="viral" post="infections. The thousandfold enhanced resolution provided by TEM enables"/>
 <result pre="thousandfold enhanced resolution provided by TEM enables investigators to visualize" exact="viral" post="morphology and to classify viruses into families [94]. Mechanistically,"/>
 <result pre="enhanced resolution provided by TEM enables investigators to visualize viral" exact="morphology" post="and to classify viruses into families [94]. Mechanistically, TEM"/>
 <result pre="of signals from transmitted electrons, before processing them to reveal" exact="viral" post="morphology and location within cells [96]. Typical specimen preparation"/>
 <result pre="signals from transmitted electrons, before processing them to reveal viral" exact="morphology" post="and location within cells [96]. Typical specimen preparation for"/>
 <result pre="97, 98]. 2019-nCoV sampling typically uses supernatants from patient airway" exact="epithelial" post="cells. Infected cells are fixed and dehydrated before embedding"/>
 <result pre="a more robust, efficient, and economical way to tackle the" exact="disease" post="is to repurpose existing drugs into a viable therapeutic"/>
 <result pre="at treatment centers for COVID-19 patients. As COVID-19 is a" exact="viral infection," post="the most obvious choices for repurposed drugs come from"/>
 <result pre="the antiviral drug creation strategies. 3.1.1. Entry Inhibitors When an" exact="infection" post="occurs, the virus gains entry into a host cell"/>
 <result pre="competitive binding or by downregulating the receptors, are known as" exact="viral" post="entry inhibitors (Figure 9(a)). These inhibitors are valuable as"/>
 <result pre="(Figure 9(a)). These inhibitors are valuable as therapeutics since blocking" exact="infection" post="early in the life cycle reduces cellular and tissue"/>
 <result pre="the life cycle reduces cellular and tissue damage associated with" exact="viral" post="replication and production of viral progeny. As mentioned above,"/>
 <result pre="and tissue damage associated with viral replication and production of" exact="viral" post="progeny. As mentioned above, coronavirus particles comprise four structural"/>
 <result pre="proteins [104â€&quot;107]. The S protein is the most crucial in" exact="viral" post="attachment, fusion, and entry [108]. It comprises two subunits."/>
 <result pre="it is vital to target ACE2 for the development of" exact="viral" post="entry inhibitors. To the best of our knowledge, not"/>
 <result pre="been used in the treatment of hypertension, cardiac diseases, and" exact="diabetes mellitus" post="to regulate the renin-angiotensin system [115, 116]. There are"/>
 <result pre="increase the expression of ACE2, which in turn may increase" exact="susceptibility to" post="viral host cell entry [120, 121]. Much work needs"/>
 <result pre="expression of ACE2, which in turn may increase susceptibility to" exact="viral" post="host cell entry [120, 121]. Much work needs to"/>
 <result pre="targets hemagglutinin for its anti-influenza virus effect [122â€&quot;124]. Hemagglutinin, a" exact="viral" post="cell surface protein, facilitates infection by undergoing a conformational"/>
 <result pre="virus effect [122â€&quot;124]. Hemagglutinin, a viral cell surface protein, facilitates" exact="infection" post="by undergoing a conformational change when the virus binds"/>
 <result pre="This renders lipid bilayers of host cells less prone to" exact="viral" post="fusion [125]. No studies have shown that umifenovir is"/>
 <result pre="an in vitro study that arbidol may effectively inhibit 2019-nCoV" exact="infection" post="at a concentration of 10-30â€‰Î¼M [128]. Chloroquine, also a"/>
 <result pre="the signaling pathway of enzymes, causing enzyme glycosylation, ultimately inhibiting" exact="viral" post="replication in host cells [133, 134]. Liu et al."/>
 <result pre="hydroxychloroquine has been administered to hospitalized 2019-nCoV patients on an" exact="uncontrolled" post="basis in various countries, including China and the USA"/>
 <result pre="However, it must be noted that chloroquine and hydroxychloroquine cause" exact="ocular" post="toxicity [142]. Hydroxychloroquine is reportedly less toxic than chloroquine,"/>
 <result pre="as cell growth and death, blood clotting, inflammation, fertilization, and" exact="infection" post="[103]. Viral entry into host cells requires S protein"/>
 <result pre="growth and death, blood clotting, inflammation, fertilization, and infection [103]." exact="Viral" post="entry into host cells requires S protein priming by"/>
 <result pre="priming by host proteases, which subsequently enables the fusion of" exact="viral" post="and cellular membranes [113]. Membrane fusion enables the release"/>
 <result pre="cellular membranes [113]. Membrane fusion enables the release of the" exact="viral" post="genome into the host cytoplasm, initiating RNA translation into"/>
 <result pre="into protein. Most viruses also encode their proteases to protect" exact="viral" post="proteins by modulating host cell responses. While proteases are"/>
 <result pre="become promising targets for antiviral therapeutic agents. Protease inhibitors prevent" exact="viral" post="replication by binding selectively to viral proteases or blocking"/>
 <result pre="agents. Protease inhibitors prevent viral replication by binding selectively to" exact="viral" post="proteases or blocking proteolytic cleavage of protein precursors necessary"/>
 <result pre="proteolytic cleavage of protein precursors necessary for the production of" exact="infectious" post="particles [144]. It is noteworthy that protease inhibitors were"/>
 <result pre="members [145]. TMPRSS family proteases are widely expressed in the" exact="respiratory" post="tract [145, 146], which is likely the reason that"/>
 <result pre="[145, 146], which is likely the reason that coronaviruses cause" exact="acute" post="respiratory distress syndrome. Upon successful priming, the viral genome"/>
 <result pre="146], which is likely the reason that coronaviruses cause acute" exact="respiratory" post="distress syndrome. Upon successful priming, the viral genome encoding"/>
 <result pre="coronaviruses cause acute respiratory distress syndrome. Upon successful priming, the" exact="viral" post="genome encoding RNA and several nonstructural proteins, including coronavirus"/>
 <result pre="are released [147â€&quot;149]. The single-stranded positive RNA is translated into" exact="viral" post="polyproteins by ribosomes in the host cell cytoplasm. The"/>
 <result pre="cytoplasm. The polyproteins are then cleaved into effector proteins by" exact="viral" post="proteases: 3CLpro and PLpro. PLpro also acts as a"/>
 <result pre="weakening the immune system [147, 149, 150]. Both host and" exact="viral" post="proteases are essential therapeutic targets in the case of"/>
 <result pre="small molecule that has shown an excellent therapeutic effect for" exact="chronic" post="pancreatitis treatment by targeting proteases [113, 151, 152]. Camostat"/>
 <result pre="molecule that has shown an excellent therapeutic effect for chronic" exact="pancreatitis" post="treatment by targeting proteases [113, 151, 152]. Camostat mesylate"/>
 <result pre="completely blocking membrane fusion between the host cell and the" exact="viral" post="MERS-CoV particle [156]. Zhou et al. claimed that camostat"/>
 <result pre="camostat mesylate displays an inhibitory effect in mice for SARS-CoV" exact="infection" post="[152]. Recent research by Hoffmann et al. showed a"/>
 <result pre="HIV-1 protease [157]. This results in the production of noncontagious" exact="viral" post="particles. On the other hand, ritonavir binds to HIV-1"/>
 <result pre="binds to HIV-1 protease, interrupting the maturation and production of" exact="viral" post="particles [158]. A clinical study from Hong Kong has"/>
 <result pre="trial using lopinavir-ritonavir in Wuhan, China, reported that 199 hospitalized" exact="adult" post="patients infected with 2019-nCoV did not benefit from the"/>
 <result pre="the acquisition of its proteolytic activity for the maturation of" exact="viral" post="particles [163]. Lin et al. claimed that darunavir inhibits"/>
 <result pre="for COVID-19. 3.1.3. Replication Inhibitors Polymerases are enzymes essential for" exact="viral" post="replication to produce viral progeny. Viral DNA and RNA"/>
 <result pre="Inhibitors Polymerases are enzymes essential for viral replication to produce" exact="viral" post="progeny. Viral DNA and RNA polymerases are responsible for"/>
 <result pre="are enzymes essential for viral replication to produce viral progeny." exact="Viral" post="DNA and RNA polymerases are responsible for duplicating the"/>
 <result pre="Viral DNA and RNA polymerases are responsible for duplicating the" exact="viral" post="genome and facilitating transcription and replication [103]. Replication inhibitors"/>
 <result pre="[103]. Replication inhibitors (Figure 9(c)) interfere with the production of" exact="viral" post="particles by blocking enzymatic activity, ultimately causing chain termination"/>
 <result pre="particles by blocking enzymatic activity, ultimately causing chain termination during" exact="viral" post="DNA or RNA replication [166]. There are four types"/>
 <result pre="DNA or RNA replication [166]. There are four types of" exact="viral" post="polymerases in viruses: RNA-dependent RNA polymerases, RdRp, DNA-dependent RNA"/>
 <result pre="RNA template to be used by RdRp to replicate more" exact="viral" post="genomic RNA, which eventually turns host cells into virus"/>
 <result pre="adenosine, and ribavirin has been used in the treatment of" exact="respiratory" post="syncytial virus [168]. It has only one ring at"/>
 <result pre="also known for its inhibitory effect on viruses by forcing" exact="viral" post="genome replication to become catastrophically error-prone. It is likely"/>
 <result pre="analog, ribavirin is incorporated by RdRp into the newly synthesized" exact="viral" post="genome, where it induces mutagenesis [170, 172]. Although ribavirin"/>
 <result pre="induces mutagenesis [170, 172]. Although ribavirin has proven effective against" exact="viral" post="infections, its mechanism of action has not been firmly"/>
 <result pre="decreased hemoglobin levels [174]. However, ribavirin was used as the" exact="primary" post="treatment during the MERS outbreak [175]. In general, clinical"/>
 <result pre="the same carboxamide moiety [180]. While ribavirin interacts with the" exact="viral" post="polymerase directly, favipiravir must be phosphoribosylated by cellular enzymes"/>
 <result pre="enzymes to its active form, favipiravir-ribofuranosyl-5â€²-triphosphate (RTP) [181, 182]. The" exact="viral" post="polymerase mistakenly recognizes favipiravir-RTP for a purine nucleotide, thereby"/>
 <result pre="polymerase mistakenly recognizes favipiravir-RTP for a purine nucleotide, thereby disrupting" exact="viral" post="genome replication [181, 182]. Favipiravir has not been used"/>
 <result pre="MERS previously, but interestingly, it has been shown to reduce" exact="viral infection" post="of 2019-nCoV [138, 183]. In a clinical study involving"/>
 <result pre="previously, but interestingly, it has been shown to reduce viral" exact="infection" post="of 2019-nCoV [138, 183]. In a clinical study involving"/>
 <result pre="China, favipiravir showed better efficacy than lopinavir-ritonavir in terms of" exact="disease" post="progression and viral clearance [183]. Another clinical study involving"/>
 <result pre="better efficacy than lopinavir-ritonavir in terms of disease progression and" exact="viral" post="clearance [183]. Another clinical study involving 240 patients with"/>
 <result pre="synthesized and developed by Gilead Science in 2017 for Ebola" exact="virus infection" post="[186]. Remdesivir needs to be metabolized into its active"/>
 <result pre="and developed by Gilead Science in 2017 for Ebola virus" exact="infection" post="[186]. Remdesivir needs to be metabolized into its active"/>
 <result pre="to initiate its activity. The active form of remdesivir inhibits" exact="viral" post="RNA polymerase and evades proofreading by viral exonuclease, causing"/>
 <result pre="of remdesivir inhibits viral RNA polymerase and evades proofreading by" exact="viral" post="exonuclease, causing an interruption in viral RNA production [138,"/>
 <result pre="and evades proofreading by viral exonuclease, causing an interruption in" exact="viral" post="RNA production [138, 185, 186]. It has been demonstrated"/>
 <result pre="It has been demonstrated that remdesivir is effective against MERS-CoV" exact="infection" post="in vivo and 2019-nCoV in vitro [138, 187], showing"/>
 <result pre="libraries and identified MTHFDI as the critical host factor for" exact="viral" post="infections [190]. MTHFDI is a trifunctional enzyme involved in"/>
 <result pre="and identified MTHFDI as the critical host factor for viral" exact="infections" post="[190]. MTHFDI is a trifunctional enzyme involved in the"/>
 <result pre="purine synthesis activity of MTHFDI is an essential activity for" exact="viral" post="replication, making MTHFDI a potential target for developing antiviral"/>
 <result pre="that an MTHFD1 inhibitor, carolacton, restricts replication of influenza virus," exact="mumps" post="virus, Melaka virus, Zika virus, and, most importantly, 2019-nCoV"/>
 <result pre="Zika virus, and, most importantly, 2019-nCoV [190]. Carolacton is a" exact="secondary" post="metabolite derived from the mycobacterium Sorangium cellulosum. It is"/>
 <result pre="recently been utilized for the treatment of diseases such as" exact="cancer" post="[198â€&quot;200] and various types of infections [201, 202]. The"/>
 <result pre="of diseases such as cancer [198â€&quot;200] and various types of" exact="infections" post="[201, 202]. The ease of modification of surface properties,"/>
 <result pre="broad antiviral properties against a multitude of viruses, including HIV," exact="hepatitis" post="B virus, herpes simplex virus, respiratory syncytial virus, and"/>
 <result pre="against a multitude of viruses, including HIV, hepatitis B virus," exact="herpes" post="simplex virus, respiratory syncytial virus, and monkeypox virus [206]."/>
 <result pre="of viruses, including HIV, hepatitis B virus, herpes simplex virus," exact="respiratory" post="syncytial virus, and monkeypox virus [206]. The broad antiviral"/>
 <result pre="hepatitis B virus, herpes simplex virus, respiratory syncytial virus, and" exact="monkeypox" post="virus [206]. The broad antiviral properties of silver nanoparticles"/>
 <result pre="drug delivery. Recently, Herold and Sander demonstrated the use of" exact="pulmonary" post="surfactant-biomimetic nanoparticles to encapsulate a stimulator of interferon gene"/>
 <result pre="in children, and it has demonstrated efficacy in reducing the" exact="viral" post="load during early stages of infection [208, 209]. Another"/>
 <result pre="efficacy in reducing the viral load during early stages of" exact="infection" post="[208, 209]. Another promising biologic drug is convalescent plasma,"/>
 <result pre="C, and D and zinc can reduce the severity of" exact="respiratory" post="infections [215â€&quot;221]. However, most of these studies targeted children"/>
 <result pre="and D and zinc can reduce the severity of respiratory" exact="infections" post="[215â€&quot;221]. However, most of these studies targeted children below"/>
 <result pre="damage induced by inflammatory reactions and immune responses initiated by" exact="viral" post="infections. Single and combined Chinese medicines could mitigate the"/>
 <result pre="2009 [228]. As of February 17, 2020, over 85.2% of" exact="total" post="confirmed cases (over 60,000 cases) had been treated with"/>
 <result pre="by faster clinical symptom disappearance and reduction of fever, shorter" exact="disease" post="course, higher cure rate (by 33%), and lower rate"/>
 <result pre="fever, shorter disease course, higher cure rate (by 33%), and" exact="lower" post="rate of moderate-to-severe cases [229]. To date, the National"/>
 <result pre="been recommended for patients based on the stage of the" exact="disease" post="and their symptoms [230]. According to the 7th edition"/>
 <result pre="It also promoted significant improvement in cases of severe community-acquired" exact="pneumonia" post="(CAP) [232]. Therefore, TCM could be an alternative prophylactic"/>
 <result pre="therapy is a promising treatment strategy for degenerative diseases, including" exact="Huntington's disease," post="Parkinson's and Alzheimer's diseases, and chronic diseases such as"/>
 <result pre="degenerative diseases, including Huntington's disease, Parkinson's and Alzheimer's diseases, and" exact="chronic" post="diseases such as cardiac failure and diabetes [233]. A"/>
 <result pre="Alzheimer's diseases, and chronic diseases such as cardiac failure and" exact="diabetes" post="[233]. A clinical study showed that transplantation of mesenchymal"/>
 <result pre="cells (MSCs) significantly lowered the mortality of patients with H7N9-induced" exact="acute" post="respiratory distress syndrome (ARDS), with no harmful effects [234]."/>
 <result pre="(MSCs) significantly lowered the mortality of patients with H7N9-induced acute" exact="respiratory" post="distress syndrome (ARDS), with no harmful effects [234]. As"/>
 <result pre="lowered the mortality of patients with H7N9-induced acute respiratory distress" exact="syndrome" post="(ARDS), with no harmful effects [234]. As H7N9 and"/>
 <result pre="As H7N9 and 2019-nCoV share similar genome structures and corresponding" exact="infection" post="mechanisms, as well as related clinical symptoms (lung failure),"/>
 <result pre="of 2019-nCoV. The other vaccine, Ad5-nCoV (a recombinant novel coronavirus" exact="disease" post="vaccine (adenovirus type 5 vector)), was conducted at Tongji"/>
 <result pre="other vaccine, Ad5-nCoV (a recombinant novel coronavirus disease vaccine (adenovirus" exact="type 5" post="vector)), was conducted at Tongji Hospital in Wuhan, China,"/>
 <result pre="engineered vaccine, expresses the 2019-nCoV S protein using replication-defective adenovirus" exact="type 5" post="as an expression vector, thereby inducing a virus-specific immune"/>
 <result pre="Significantly, the MNA work can be extended to other emerging" exact="infectious diseases." post="However, these will require further clinical studies for efficacy"/>
 <result pre="they also need additional treatments, according to their symptoms, including" exact="respiratory" post="support (oxygen therapy, high-flow nasal cannulas, or noninvasive ventilation,"/>
 <result pre="most recent pandemic, COVID-19 induces much fear. It is highly" exact="infectious" post="and is transmitted asymptomatically. As such, our best options"/>
 <result pre="understand the origin of 2019-nCoV, its transmission route, and associated" exact="disease" post="pathways and systems. Generally, a pathogen must remain viable"/>
 <result pre="the human body (up to 72 hours) and is more" exact="stable" post="on plastic and stainless steel than on copper and"/>
 <result pre="patients. As such, contact tracing is still a mainstay for" exact="disease" post="control. Confirmation can be achieved only when specific diagnostic"/>
 <result pre="it is recommended for suspected COVID-19 cases [242]. Once the" exact="primary" post="diagnosis reveals abnormal chest CT findings, a nucleic acid"/>
 <result pre="suspected COVID-19 cases [242]. Once the primary diagnosis reveals abnormal" exact="chest" post="CT findings, a nucleic acid test should be performed"/>
 <result pre="person is confirmed positive, tests such as C-reactive protein (CRP)," exact="complete" post="blood count, urinalysis, biochemical indicators (i.e., liver enzymes, myocardial"/>
 <result pre="beyond, strict controls over human traffic are essential to limiting" exact="disease" post="transmission. By establishing lockdowns, China has been able to"/>
 <result pre="epidemics, does not recognize political boundaries, ethnicity, or gender. The" exact="disease" post="has challenged the economic and medical infrastructure of the"/>
 <result pre="molecular virological techniques have assisted the scientific community in characterizing" exact="infectious" post="agents for years. These include qRT-PCR, isothermal amplification, and"/>
 <result pre="supports the design of functional vaccine approaches. Other approaches, including" exact="chest" post="computed tomography (CT) and transmission electron microscopy (TEM), can"/>
 <result pre="of rapid, accurate diagnostic devices and strategies to characterize unknown" exact="respiratory" post="pathogens. Despite these signs of progress, the present data"/>
 <result pre="alone may not be sufficient to eradicate COVID-19 in the" exact="short" post="term. Efficacious and novel treatments are desperately required. Presently,"/>
 <result pre="The authors declare no conflicts of interest. References 1collab: WHOCoronavirus" exact="disease" post="(COVID-19) outbreak situation2020https://www.who.int/emergencies/diseases/novel-coronavirus-2019 2collab: WHO2019-nCoV outbreak is an emergency"/>
 <result pre="of Virology20128673995400810.1128/JVI.06540-1122278237 6WooP. C. Y.LauS. K. P.ChuC. M.et al.Characterization and" exact="complete" post="genome sequence of a novel coronavirus, coronavirus HKU1, from"/>
 <result pre="7PeirisJ.LaiS. T.PoonL. L.et al.Coronavirus as a possible cause of severe" exact="acute" post="respiratory syndromeThe Lancet200336193661319132510.1016/S0140-6736(03)13077-212711465 8ZhuN.ZhangD.WangW.et al.A novel coronavirus from patients"/>
 <result pre="T.PoonL. L.et al.Coronavirus as a possible cause of severe acute" exact="respiratory" post="syndromeThe Lancet200336193661319132510.1016/S0140-6736(03)13077-212711465 8ZhuN.ZhangD.WangW.et al.A novel coronavirus from patients with"/>
 <result pre="respiratory syndromeThe Lancet200336193661319132510.1016/S0140-6736(03)13077-212711465 8ZhuN.ZhangD.WangW.et al.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019The New England Journal of Medicine2020382872773310.1056/NEJMoa200101731978945 9GralinskiL."/>
 <result pre="D.Return of the coronavirus: 2019-nCoVViruses2020122p. 13510.3390/v1202013531991541 10ZhouP.YangX. L.WangX. G.et al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting WuhanEmerging Microbes &amp;amp; Infections20209122123610.1080/22221751.2020.171990231987001 13ChenY.LiuQ.GuoD.Emerging coronaviruses: genome"/>
 <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerging Microbes &amp;amp; Infections20209122123610.1080/22221751.2020.171990231987001 13ChenY.LiuQ.GuoD.Emerging coronaviruses: genome"/>
 <result pre="and pathogenesisJournal of Medical Virology202092441842310.1002/jmv.2568131967327 14WangJ.ZhaoS.LiuM.et al.ACE2 expression by colonic" exact="epithelial" post="cells is associated with viral infection, immunity and energy"/>
 <result pre="14WangJ.ZhaoS.LiuM.et al.ACE2 expression by colonic epithelial cells is associated with" exact="viral infection," post="immunity and energy metabolism2020medRxiv10.1101/2020.02.05.20020545 15ZouX.ChenK.ZouJ.HanP.HaoJ.HanZ.Single-cell RNA-seq data analysis on"/>
 <result pre="assemblyVirology2015478758510.1016/j.virol.2015.02.00525726972 20Nieto-TorresJ. L.DeDiegoM. L.Ã�lvarezE.et al.Subcellular location and topology of severe" exact="acute" post="respiratory syndrome coronavirus envelope proteinVirology20114152698210.1016/j.virol.2011.03.02921524776 21RuchT. R.MachamerC. E.A single"/>
 <result pre="20Nieto-TorresJ. L.DeDiegoM. L.Ã�lvarezE.et al.Subcellular location and topology of severe acute" exact="respiratory" post="syndrome coronavirus envelope proteinVirology20114152698210.1016/j.virol.2011.03.02921524776 21RuchT. R.MachamerC. E.A single polar"/>
 <result pre="L.DeDiegoM. L.Ã�lvarezE.et al.Subcellular location and topology of severe acute respiratory" exact="syndrome" post="coronavirus envelope proteinVirology20114152698210.1016/j.virol.2011.03.02921524776 21RuchT. R.MachamerC. E.A single polar residue"/>
 <result pre="residue and distinct membrane topologies impact the function of the" exact="infectious" post="bronchitis coronavirus E proteinPLoS Pathogens201285, article e100267410.1371/journal.ppat.100267422570613 22AbdelmageedM. I.AbdelmoneimA."/>
 <result pre="and distinct membrane topologies impact the function of the infectious" exact="bronchitis" post="coronavirus E proteinPLoS Pathogens201285, article e100267410.1371/journal.ppat.100267422570613 22AbdelmageedM. I.AbdelmoneimA. H.MustafaM."/>
 <result pre="approach2020BioRxiv10.1101/2020.02.04.934232 23collab: WHOReport of the WHO-China joint mission on coronavirus" exact="disease" post="2019 (COVID-19)2020https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf 24SurveillancesV.The epidemiological characteristics of an outbreak of"/>
 <result pre="sequencing for accurate and comprehensive detection of SARS-CoV-2 and other" exact="respiratory" post="viruses2020MedRxiv10.1101/2020.03.04.20029538 29WeiS.WeissZ. R.WilliamsZ.Rapid multiplex small DNA sequencing on the"/>
 <result pre="(LAMP): a rapid, accurate, and cost- effective diagnostic method for" exact="infectious" post="diseasesJournal of Infection and Chemotherapy2009152626910.1007/s10156-009-0669-919396514 38LiC.YingQ.SuX.LiT.Development and application of"/>
 <result pre="accurate, and cost- effective diagnostic method for infectious diseasesJournal of" exact="Infection" post="and Chemotherapy2009152626910.1007/s10156-009-0669-919396514 38LiC.YingQ.SuX.LiT.Development and application of reverse transcription loop-mediated"/>
 <result pre="H.et al.Development of Reverse Transcription Loop-Mediated Isothermal Amplification Assays Targeting" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2The Journal of Molecular Diagnostics202010.1016/j.jmoldx.2020.03.006"/>
 <result pre="al.Development of Reverse Transcription Loop-Mediated Isothermal Amplification Assays Targeting Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2The Journal of Molecular Diagnostics202010.1016/j.jmoldx.2020.03.006 44YangW.DangX.WangQ.et"/>
 <result pre="of Reverse Transcription Loop-Mediated Isothermal Amplification Assays Targeting Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2The Journal of Molecular Diagnostics202010.1016/j.jmoldx.2020.03.006 44YangW.DangX.WangQ.et al.Rapid"/>
 <result pre="Reverse Transcription Loop-Mediated Isothermal Amplification Assays Targeting Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2The Journal of Molecular Diagnostics202010.1016/j.jmoldx.2020.03.006 44YangW.DangX.WangQ.et al.Rapid detection"/>
 <result pre="transcription recombinase polymerase amplification assay for rapid detection of foot-and-mouth" exact="disease" post="virusPLoS One201388, article e7164210.1371/journal.pone.007164223977101 49BoyleD. S.LehmanD. A.LillisL.et al.Rapid detection"/>
 <result pre="recombinase polymerase amplification assay for the detection of Middle East" exact="respiratory" post="syndrome coronavirusPLoS Currents2013510.1371/currents.outbreaks.62df1c7c75ffc96cd59034531e2e8364 52YanT.LiX. N.WangL.et al.Development of a reverse"/>
 <result pre="polymerase amplification assay for the detection of Middle East respiratory" exact="syndrome" post="coronavirusPLoS Currents2013510.1371/currents.outbreaks.62df1c7c75ffc96cd59034531e2e8364 52YanT.LiX. N.WangL.et al.Development of a reverse transcription"/>
 <result pre="for the first timeNature20165397630p. 47910.1038/nature.2016.2098827882996 56RezaeiH.khademparS.FarahaniN.et al.Harnessing CRISPR/Cas9 technology in" exact="cardiovascular" post="diseaseTrends in Cardiovascular Medicine20203029310110.1016/j.tcm.2019.03.00530935726 57GootenbergJ. S.AbudayyehO. O.LeeJ. W.et al.Nucleic"/>
 <result pre="77LauS. K. P.WooP. C. Y.WongB. H. L.et al.Detection of severe" exact="acute" post="respiratory syndrome (SARS) coronavirus nucleocapsid protein in sars patients"/>
 <result pre="K. P.WooP. C. Y.WongB. H. L.et al.Detection of severe acute" exact="respiratory" post="syndrome (SARS) coronavirus nucleocapsid protein in sars patients by"/>
 <result pre="P.WooP. C. Y.WongB. H. L.et al.Detection of severe acute respiratory" exact="syndrome" post="(SARS) coronavirus nucleocapsid protein in sars patients by enzyme-linked"/>
 <result pre="C. Y.LauS. K. P.WongB. H. L.et al.Differential sensitivities of severe" exact="acute" post="respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay"/>
 <result pre="Y.LauS. K. P.WongB. H. L.et al.Differential sensitivities of severe acute" exact="respiratory" post="syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA)"/>
 <result pre="K. P.WongB. H. L.et al.Differential sensitivities of severe acute respiratory" exact="syndrome" post="(SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and"/>
 <result pre="application of a rapid IgM-IgG combined antibody test for SARS-CoV-2" exact="infection" post="diagnosisJournal of Medical Virology202010.1002/jmv.25727 85HosseinyM.KoorakiS.GholamrezanezhadA.ReddyS.MyersL.Radiology perspective of coronavirus disease"/>
 <result pre="SARS-CoV-2 infection diagnosisJournal of Medical Virology202010.1002/jmv.25727 85HosseinyM.KoorakiS.GholamrezanezhadA.ReddyS.MyersL.Radiology perspective of coronavirus" exact="disease" post="2019 (COVID-19): lessons from severe acute respiratory syndrome and"/>
 <result pre="85HosseinyM.KoorakiS.GholamrezanezhadA.ReddyS.MyersL.Radiology perspective of coronavirus disease 2019 (COVID-19): lessons from severe" exact="acute" post="respiratory syndrome and Middle East respiratory syndromeAJR American Journal"/>
 <result pre="perspective of coronavirus disease 2019 (COVID-19): lessons from severe acute" exact="respiratory" post="syndrome and Middle East respiratory syndromeAJR American Journal of"/>
 <result pre="of coronavirus disease 2019 (COVID-19): lessons from severe acute respiratory" exact="syndrome" post="and Middle East respiratory syndromeAJR American Journal of Roentgenology202021451078108210.2214/AJR.20.2296932108495"/>
 <result pre="(COVID-19): lessons from severe acute respiratory syndrome and Middle East" exact="respiratory" post="syndromeAJR American Journal of Roentgenology202021451078108210.2214/AJR.20.2296932108495 86KetaiL.PaulN. S.WongK. T.Radiology of"/>
 <result pre="from severe acute respiratory syndrome and Middle East respiratory syndromeAJR" exact="American" post="Journal of Roentgenology202021451078108210.2214/AJR.20.2296932108495 86KetaiL.PaulN. S.WongK. T.Radiology of severe acute"/>
 <result pre="syndromeAJR American Journal of Roentgenology202021451078108210.2214/AJR.20.2296932108495 86KetaiL.PaulN. S.WongK. T.Radiology of severe" exact="acute" post="respiratory syndrome (SARS): the emerging pathologic-radiologic correlates of an"/>
 <result pre="American Journal of Roentgenology202021451078108210.2214/AJR.20.2296932108495 86KetaiL.PaulN. S.WongK. T.Radiology of severe acute" exact="respiratory" post="syndrome (SARS): the emerging pathologic-radiologic correlates of an emerging"/>
 <result pre="Journal of Roentgenology202021451078108210.2214/AJR.20.2296932108495 86KetaiL.PaulN. S.WongK. T.Radiology of severe acute respiratory" exact="syndrome" post="(SARS): the emerging pathologic-radiologic correlates of an emerging diseaseJournal"/>
 <result pre="(SARS): the emerging pathologic-radiologic correlates of an emerging diseaseJournal of" exact="Thoracic" post="Imaging200621427628310.1097/01.rti.0000213581.14225.f117110851 87DasK. M.LeeE. Y.LangerR. D.LarssonS. G.Middle East respiratory syndrome"/>
 <result pre="diseaseJournal of Thoracic Imaging200621427628310.1097/01.rti.0000213581.14225.f117110851 87DasK. M.LeeE. Y.LangerR. D.LarssonS. G.Middle East" exact="respiratory" post="syndrome coronavirus: what does a radiologist need to know?American"/>
 <result pre="of Thoracic Imaging200621427628310.1097/01.rti.0000213581.14225.f117110851 87DasK. M.LeeE. Y.LangerR. D.LarssonS. G.Middle East respiratory" exact="syndrome" post="coronavirus: what does a radiologist need to know?American Journal"/>
 <result pre="need to know?American Journal of Roentgenology201620661193120110.2214/AJR.15.1536326998804 88DasK. M.LeeE. Y.SinghR.et al.Follow-up" exact="chest" post="radiographic findings in patients with MERS-CoV after recoveryIndian Journal"/>
 <result pre="H.et al.Chest radiograph scores as potential prognostic indicators in severe" exact="acute" post="respiratory syndrome (SARS)American Journal of Roentgenology2005184373474110.2214/ajr.184.3.0184073415728590 90ChungM.BernheimA.MeiX.et al.CT imaging"/>
 <result pre="al.Chest radiograph scores as potential prognostic indicators in severe acute" exact="respiratory" post="syndrome (SARS)American Journal of Roentgenology2005184373474110.2214/ajr.184.3.0184073415728590 90ChungM.BernheimA.MeiX.et al.CT imaging features"/>
 <result pre="radiograph scores as potential prognostic indicators in severe acute respiratory" exact="syndrome" post="(SARS)American Journal of Roentgenology2005184373474110.2214/ajr.184.3.0184073415728590 90ChungM.BernheimA.MeiX.et al.CT imaging features of"/>
 <result pre="features of 2019 novel coronavirus (2019-nCoV)Radiology2020295120220710.1148/radiol.202020023032017661 91ChanJ. F.-W.YuanS.KokK. H.et al.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
 <result pre="novel coronavirus (2019-nCoV)Radiology2020295120220710.1148/radiol.202020023032017661 91ChanJ. F.-W.YuanS.KokK. H.et al.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
 <result pre="94CurryA.AppletonH.DowsettB.Application of transmission electron microscopy to the clinical study of" exact="viral" post="and bacterial infections: present and futureMicron20063729110610.1016/j.micron.2005.10.00116361103 95LiuX.DengR.ZhangY.et al.Probing the"/>
 <result pre="transmission electron microscopy to the clinical study of viral and" exact="bacterial" post="infections: present and futureMicron20063729110610.1016/j.micron.2005.10.00116361103 95LiuX.DengR.ZhangY.et al.Probing the nature of"/>
 <result pre="coronavirus replicates in cells2020https://www.bloomberg.com/news/articles/2020-01-31/here-are-the-first-images-of-how-coronavirus-replicates-in-cells 98MonningerM. K.NguessanC. A.BlancettC. D.et al.Preparation of" exact="viral" post="samples within biocontainment for ultrastructural analysis: utilization of an"/>
 <result pre="100AstinJ. W.KeerthisingheP.DuL.SandersonL. E.CrosierK. E.HallC. J.DetrichH. W.WesterfieldM.ZonL. I.Innate immune cells and" exact="bacterial infection" post="in zebrafishMethods in Cell Biology2017138Academic Press3160 101OpreaT. I.BaumanJ. E.BologaC."/>
 <result pre="W.KeerthisingheP.DuL.SandersonL. E.CrosierK. E.HallC. J.DetrichH. W.WesterfieldM.ZonL. I.Innate immune cells and bacterial" exact="infection" post="in zebrafishMethods in Cell Biology2017138Academic Press3160 101OpreaT. I.BaumanJ. E.BologaC."/>
 <result pre="Therapeutic Strategies201183-4616910.1016/j.ddstr.2011.10.00222368688 102PizzornoA.PadeyB.TerrierO.Rosa-CalatravaM.Drug repurposing approaches for the treatment of influenza" exact="viral" post="infection: reviving old drugs to fight against a long-lived"/>
 <result pre="novel coronavirus: implication for development of RBD protein as a" exact="viral" post="attachment inhibitor and vaccineCellular &amp;amp; Molecular Immunology202010.1038/s41423-020-0400-4 105WangN.ShangJ.JiangS.DuL.Subunit vaccines"/>
 <result pre="K.LicitraB. N.WhittakerG. R.Mechanisms of coronavirus cell entry mediated by the" exact="viral" post="spike proteinViruses2012461011103310.3390/v406101122816037 109LiW.MooreM. J.VasilievaN.et al.Angiotensin-converting enzyme 2 is a"/>
 <result pre="R.ShaoZ.TangW. H. W.Angiotensin-converting enzyme 2 as a therapeutic target for" exact="heart" post="failureCurrent Heart Failure Reports2014111586310.1007/s11897-013-0178-024293035 117HasvoldL. P.BodegÃ¥rdJ.ThuressonM.et al.Diabetes and CVD"/>
 <result pre="W.Angiotensin-converting enzyme 2 as a therapeutic target for heart failureCurrent" exact="Heart Failure" post="Reports2014111586310.1007/s11897-013-0178-024293035 117HasvoldL. P.BodegÃ¥rdJ.ThuressonM.et al.Diabetes and CVD risk during angiotensin-converting"/>
 <result pre="enzyme 2 as a therapeutic target for heart failureCurrent Heart" exact="Failure" post="Reports2014111586310.1007/s11897-013-0178-024293035 117HasvoldL. P.BodegÃ¥rdJ.ThuressonM.et al.Diabetes and CVD risk during angiotensin-converting"/>
 <result pre="of human hypertension2014281166366910.1038/jhh.2014.4325211055 118WhiteW. B.WilsonC.BakrisG.et al.Ace inhibitor use and major" exact="cardiovascular" post="outcomes in type 2 diabetes treated with the dpp-4"/>
 <result pre="118WhiteW. B.WilsonC.BakrisG.et al.Ace inhibitor use and major cardiovascular outcomes in" exact="type 2" post="diabetes treated with the dpp-4 inhibitor alogliptinJournal of the"/>
 <result pre="al.Ace inhibitor use and major cardiovascular outcomes in type 2" exact="diabetes" post="treated with the dpp-4 inhibitor alogliptinJournal of the American"/>
 <result pre="2 diabetes treated with the dpp-4 inhibitor alogliptinJournal of the" exact="American" post="College of Cardiology20156510, article A141110.1016/S0735-1097(15)61411-5 119RiceG. I.ThomasD. A.GrantP. J.TurnerA."/>
 <result pre="angiotensin-converting enzyme inhibitors and angiotensin receptor BlockersThe Journal of the" exact="American" post="Medical Association2020323181749186210.1001/jama.2020.4812 121FangL.KarakiulakisG.RothM.Are patients with hypertension and diabetes mellitus"/>
 <result pre="BlockersThe Journal of the American Medical Association2020323181749186210.1001/jama.2020.4812 121FangL.KarakiulakisG.RothM.Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?The"/>
 <result pre="of the American Medical Association2020323181749186210.1001/jama.2020.4812 121FangL.KarakiulakisG.RothM.Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?The Lancet Respiratory Medicine202084,"/>
 <result pre="and diabetes mellitus at increased risk for COVID-19 infection?The Lancet" exact="Respiratory" post="Medicine202084, article e2110.1016/S2213-2600(20)30116-832171062 122KadamR. U.WilsonI. A.Structural basis of influenza"/>
 <result pre="and therapeutic procedure for four cases with 2019 novel coronavirus" exact="pneumonia" post="receiving combined Chinese and Western medicine treatmentBioScience Trends2020141646810.5582/bst.2020.0103032037389 128DongL.HuS.GaoJ.Discovering"/>
 <result pre="and Western medicine treatmentBioScience Trends2020141646810.5582/bst.2020.0103032037389 128DongL.HuS.GaoJ.Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discoveries &amp;amp; Therapeutics2020141586010.5582/ddt.2020.0101232147628 129SavarinoA.BoelaertJ. R.CassoneA.MajoriG.CaudaR.Effects of chloroquine"/>
 <result pre="2019 (COVID-19)Drug Discoveries &amp;amp; Therapeutics2020141586010.5582/ddt.2020.0101232147628 129SavarinoA.BoelaertJ. R.CassoneA.MajoriG.CaudaR.Effects of chloroquine on" exact="viral" post="infections: an old drug against today's diseasesThe Lancet Infectious"/>
 <result pre="on viral infections: an old drug against today's diseasesThe Lancet" exact="Infectious" post="Diseases200331172272710.1016/S1473-3099(03)00806-514592603 130PooleB.OhkumaS.Effect of weak bases on the intralysosomal pH"/>
 <result pre="133SavarinoA.Di TraniL.DonatelliI.CaudaR.CassoneA.New insights into the antiviral effects of chloroquineThe Lancet" exact="Infectious" post="Diseases200662676910.1016/S1473-3099(06)70361-916439323 134SavarinoA.LuciaM. B.RastrelliE.et al.Anti-HIV effects of chloroquine: inhibition of"/>
 <result pre="Infectious Diseases200662676910.1016/S1473-3099(06)70361-916439323 134SavarinoA.LuciaM. B.RastrelliE.et al.Anti-HIV effects of chloroquine: inhibition of" exact="viral" post="particle glycosylation and synergism with protease inhibitorsJAIDS Journal of"/>
 <result pre="viral particle glycosylation and synergism with protease inhibitorsJAIDS Journal of" exact="Acquired" post="Immune Deficiency Syndromes200435322323210.1097/00126334-200403010-0000215076236 135LiuJ.CaoR.XuM.et al.Hydroxychloroquine, a less toxic derivative"/>
 <result pre="glycosylation and synergism with protease inhibitorsJAIDS Journal of Acquired Immune" exact="Deficiency" post="Syndromes200435322323210.1097/00126334-200403010-0000215076236 135LiuJ.CaoR.XuM.et al.Hydroxychloroquine, a less toxic derivative of chloroquine,"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discovery202061p. 1610.1038/s41421-020-0156-0 136VincentM. J.BergeronE.BenjannetS.et al.Chloroquine is a"/>
 <result pre="136VincentM. J.BergeronE.BenjannetS.et al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirology Journal200521p. 6910.1186/1743-422X-2-69 137KeyaertsE.VijgenL.MaesP.NeytsJ.RanstM. V.In vitro inhibition of"/>
 <result pre="and spreadVirology Journal200521p. 6910.1186/1743-422X-2-69 137KeyaertsE.VijgenL.MaesP.NeytsJ.RanstM. V.In vitro inhibition of severe" exact="acute" post="respiratory syndrome coronavirus by chloroquineBiochemical and Biophysical Research Communications2004323126426810.1016/j.bbrc.2004.08.08515351731"/>
 <result pre="spreadVirology Journal200521p. 6910.1186/1743-422X-2-69 137KeyaertsE.VijgenL.MaesP.NeytsJ.RanstM. V.In vitro inhibition of severe acute" exact="respiratory" post="syndrome coronavirus by chloroquineBiochemical and Biophysical Research Communications2004323126426810.1016/j.bbrc.2004.08.08515351731 138WangM.CaoR.ZhangL.et"/>
 <result pre="Journal200521p. 6910.1186/1743-422X-2-69 137KeyaertsE.VijgenL.MaesP.NeytsJ.RanstM. V.In vitro inhibition of severe acute respiratory" exact="syndrome" post="coronavirus by chloroquineBiochemical and Biophysical Research Communications2004323126426810.1016/j.bbrc.2004.08.08515351731 138WangM.CaoR.ZhangL.et al.Remdesivir"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBioScience Trends2020141727310.5582/bst.2020.0104732074550 140ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine and hydroxychloroquine as available"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases202010.1093/cid/ciaa237 142PasadhikaS.FishmanG. A.Effects"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases202010.1093/cid/ciaa237 142PasadhikaS.FishmanG. A.Effects of"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases202010.1093/cid/ciaa237 142PasadhikaS.FishmanG. A.Effects of chronic"/>
 <result pre="the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical" exact="Infectious" post="Diseases202010.1093/cid/ciaa237 142PasadhikaS.FishmanG. A.Effects of chronic exposure to hydroxychloroquine or"/>
 <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases202010.1093/cid/ciaa237 142PasadhikaS.FishmanG. A.Effects of" exact="chronic" post="exposure to hydroxychloroquine or chloroquine on inner retinal structuresEye201024234034610.1038/eye.2009.6519373270"/>
 <result pre="retinal structuresEye201024234034610.1038/eye.2009.6519373270 143McChesneyE. W.Animal toxicity and pharmacokinetics of hydroxychloroquine sulfateThe" exact="American" post="Journal of Medicine1983751111810.1016/0002-9343(83)91265-26408923 144KonvalinkaJ.KrÃ¤usslichH.-G.MÃ¼llerB.Retroviral proteases and their roles in"/>
 <result pre="TMPRSS2 and HAT are expressed at multiple sites in human" exact="respiratory" post="and gastrointestinal tractsPLoS One201274, article e3587610.1371/journal.pone.003587622558251 147LiuC.ZhouQ.LiY.et al.Research and"/>
 <result pre="agents and vaccines for COVID-19 and related human coronavirus diseasesACS" exact="Central" post="Science20206331533110.1021/acscentsci.0c0027232226821 148ZiebuhrJ.SnijderE. J.GorbalenyaA. E.Virus-encoded proteinases and proteolytic processing in"/>
 <result pre="J.GorbalenyaA. E.Virus-encoded proteinases and proteolytic processing in the NidoviralesJournal of" exact="General" post="Virology200081485387910.1099/0022-1317-81-4-85310725411 149BÃ¡ez-SantosY. M.St JohnS. E.MesecarA. D.The SARS-coronavirus papain-like protease:"/>
 <result pre="of Molecular Biology200535351137115110.1016/j.jmb.2005.09.00416219322 151KawaseM.ShiratoK.van der HoekL.TaguchiF.MatsuyamaS.Simultaneous treatment of human bronchial" exact="epithelial" post="cells with serine and cysteine protease inhibitors prevents severe"/>
 <result pre="epithelial cells with serine and cysteine protease inhibitors prevents severe" exact="acute" post="respiratory syndrome coronavirus entryJournal of Virology201286126537654510.1128/JVI.00094-1222496216 152ZhouY.VedanthamP.LuK.et al.Protease inhibitors"/>
 <result pre="cells with serine and cysteine protease inhibitors prevents severe acute" exact="respiratory" post="syndrome coronavirus entryJournal of Virology201286126537654510.1128/JVI.00094-1222496216 152ZhouY.VedanthamP.LuK.et al.Protease inhibitors targeting"/>
 <result pre="with serine and cysteine protease inhibitors prevents severe acute respiratory" exact="syndrome" post="coronavirus entryJournal of Virology201286126537654510.1128/JVI.00094-1222496216 152ZhouY.VedanthamP.LuK.et al.Protease inhibitors targeting coronavirus"/>
 <result pre="camostat mesilate suppresses pancreatic pain in rodentsLife Sciences200780211999200410.1016/j.lfs.2007.02.04417433371 156ShiratoK.KawaseM.MatsuyamaS.Middle East" exact="respiratory" post="syndrome coronavirus infection mediated by the transmembrane serine protease"/>
 <result pre="mesilate suppresses pancreatic pain in rodentsLife Sciences200780211999200410.1016/j.lfs.2007.02.04417433371 156ShiratoK.KawaseM.MatsuyamaS.Middle East respiratory" exact="syndrome" post="coronavirus infection mediated by the transmembrane serine protease TMPRSS2Journal"/>
 <result pre="pancreatic pain in rodentsLife Sciences200780211999200410.1016/j.lfs.2007.02.04417433371 156ShiratoK.KawaseM.MatsuyamaS.Middle East respiratory syndrome coronavirus" exact="infection" post="mediated by the transmembrane serine protease TMPRSS2Journal of Virology20138723125521256110.1128/JVI.01890-1324027332"/>
 <result pre="the binding effect of ritonavir, lopinavir and darunavir to severe" exact="acute" post="respiratory syndrome coronavirus 2 proteases2020bioRxiv10.1101/2020.01.31.929695 165EckhardtB. J.GulickR. M.CohenJ.PowderlyW. G.OpalS."/>
 <result pre="binding effect of ritonavir, lopinavir and darunavir to severe acute" exact="respiratory" post="syndrome coronavirus 2 proteases2020bioRxiv10.1101/2020.01.31.929695 165EckhardtB. J.GulickR. M.CohenJ.PowderlyW. G.OpalS. M.Drugs"/>
 <result pre="effect of ritonavir, lopinavir and darunavir to severe acute respiratory" exact="syndrome" post="coronavirus 2 proteases2020bioRxiv10.1101/2020.01.31.929695 165EckhardtB. J.GulickR. M.CohenJ.PowderlyW. G.OpalS. M.Drugs for"/>
 <result pre="2 proteases2020bioRxiv10.1101/2020.01.31.929695 165EckhardtB. J.GulickR. M.CohenJ.PowderlyW. G.OpalS. M.Drugs for HIV InfectionInfectious" exact="Diseases" post="(Fourth Edition)2017Elsevier12931308. e210.1016/B978-0-7020-6285-8.00152-0 166MagdenJ.KÃ¤Ã¤riÃ¤inenL.AholaT.Inhibitors of virus replication: recent developments"/>
 <result pre="application and mechanism of action of ribavirin in therapy of" exact="hepatitis" post="CAntiviral Chemistry and Chemotherapy201223111210.3851/IMP212522592135 169CrottyS.MaagD.ArnoldJ. J.et al.The broad-spectrum antiviral"/>
 <result pre="S.RandallG.JensenD. M.Mechanism of action of ribavirin in the treatment of" exact="chronic hepatitis" post="CGastroenterology &amp;amp; Hepatology20073321822521960835 174TaiD. Y.Pharmacologic treatment of SARS: current"/>
 <result pre="M.Mechanism of action of ribavirin in the treatment of chronic" exact="hepatitis" post="CGastroenterology &amp;amp; Hepatology20073321822521960835 174TaiD. Y.Pharmacologic treatment of SARS: current"/>
 <result pre="current knowledge and recommendationsAnnals Academy of Medicine200736438443 175DyallJ.GrossR.KindrachukJ.et al.Middle East" exact="respiratory" post="syndrome and severe acute respiratory syndrome: current therapeutic options"/>
 <result pre="knowledge and recommendationsAnnals Academy of Medicine200736438443 175DyallJ.GrossR.KindrachukJ.et al.Middle East respiratory" exact="syndrome" post="and severe acute respiratory syndrome: current therapeutic options and"/>
 <result pre="Academy of Medicine200736438443 175DyallJ.GrossR.KindrachukJ.et al.Middle East respiratory syndrome and severe" exact="acute" post="respiratory syndrome: current therapeutic options and potential targets for"/>
 <result pre="of Medicine200736438443 175DyallJ.GrossR.KindrachukJ.et al.Middle East respiratory syndrome and severe acute" exact="respiratory" post="syndrome: current therapeutic options and potential targets for novel"/>
 <result pre="and interferon therapy in patients infected with the Middle East" exact="respiratory" post="syndrome coronavirus: an observational studyInternational Journal of Infectious Diseases201420424610.1016/j.ijid.2013.12.00324406736"/>
 <result pre="interferon therapy in patients infected with the Middle East respiratory" exact="syndrome" post="coronavirus: an observational studyInternational Journal of Infectious Diseases201420424610.1016/j.ijid.2013.12.00324406736 177MomattinH.MohammedK.ZumlaA.MemishZ."/>
 <result pre="Middle East respiratory syndrome coronavirus: an observational studyInternational Journal of" exact="Infectious" post="Diseases201420424610.1016/j.ijid.2013.12.00324406736 177MomattinH.MohammedK.ZumlaA.MemishZ. A.Al-TawfiqJ. A.Therapeutic Options for Middle East Respiratory"/>
 <result pre="of Infectious Diseases201420424610.1016/j.ijid.2013.12.00324406736 177MomattinH.MohammedK.ZumlaA.MemishZ. A.Al-TawfiqJ. A.Therapeutic Options for Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS- CoV) â€&quot; possible lessons from a"/>
 <result pre="Infectious Diseases201420424610.1016/j.ijid.2013.12.00324406736 177MomattinH.MohammedK.ZumlaA.MemishZ. A.Al-TawfiqJ. A.Therapeutic Options for Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS- CoV) â€&quot; possible lessons from a systematic"/>
 <result pre="lessons from a systematic review of SARS-CoV therapyInternational Journal of" exact="Infectious" post="Diseases20131710e792e79810.1016/j.ijid.2013.07.00223993766 178ChongY. P.SongJ. Y.SeoY. B.ChoiJ. P.ShinH. S.Rapid Response TeamAntiviral"/>
 <result pre="B.ChoiJ. P.ShinH. S.Rapid Response TeamAntiviral treatment guidelines for Middle East" exact="respiratory" post="syndromeInfection &amp;amp; Chemotherapy201547321222210.3947/ic.2015.47.3.21226483999 179AbdelnabiR.MoraisA. T. S. .LeyssenP.et al.Understanding the"/>
 <result pre="favipiravir (T-705): key role of the F1 motif of the" exact="viral" post="polymeraseJournal of Virology2017911210.1128/jvi.00487-17 180PettiniF.TrezzaA.SpigaO.A Focus on Ebola Virus PolymeraseViral"/>
 <result pre="Virus PolymeraseViral Polymerases201918121010.1016/b978-0-12-815422-9.00007-3 181FurutaY.GowenB. B.TakahashiK.ShirakiK.SmeeD. F.BarnardD. L.Favipiravir (T-705), a novel" exact="viral" post="RNA polymerase inhibitorAntiviral Research2013100244645410.1016/j.antiviral.2013.09.01524084488 182FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum"/>
 <result pre="polymerase inhibitorAntiviral Research2013100244645410.1016/j.antiviral.2013.09.01524084488 182FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProceedings of the Japan Academy, Series B201793744946310.2183/pjab.93.02728769016 183CaiQ.YangM.LiuD.et"/>
 <result pre="as a possible therapeutic option for the COVID-19Travel Medicine and" exact="Infectious" post="Disease20203410.1016/j.tmaid.2020.101615 187SheahanT. P.SimsA. C.LeistS. R.et al.Comparative therapeutic efficacy of"/>
 <result pre="and interferon beta against MERS-CoVNature Communications2020111p. 22210.1038/s41467-019-13940-631924756 188collab: Centers for" exact="Disease" post="Control and PreventionInformation for clinicians on therapeutic options for"/>
 <result pre="on therapeutic options for COVID-19 patients2020https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html 189collab: Chinese Centre for" exact="Disease" post="Control and PreventionCOVID-19 prevention and control: diagnosis and treatment2020http://www.chinacdc.cn/en/COVID19/202002/P020200310326343385431.pdf"/>
 <result pre="e0037510.1128/mspheredirect.00375-1728959742 194KunzeB.ReckM.DÃ¶tschA.et al.Damage of Streptococcus mutans biofilms by carolacton, a" exact="secondary" post="metabolite from the myxobacterium Sorangium cellulosumBMC Microbiology2010101p. 19910.1186/1471-2180-10-199 195SainasS.DosioF.BoschiD.LolliM."/>
 <result pre="mesoporous cerium oxide hollow biophotocatalyst for concurrent pH-/H2O2-responsive O2-evolving synergetic" exact="cancer" post="therapyAdvanced Materials2018307, article 170483310.1002/adma.201704833 201GaoG.JiangY.-W.JiaH.-R.WuF.-G.Near-infrared light-controllable on-demand antibiotics release"/>
 <result pre="antibiotics release using thermo- sensitive hydrogel-based drug reservoir for combating" exact="bacterial" post="infectionBiomaterials2019188839510.1016/j.biomaterials.2018.09.04530339942 202MarcandalliJ.FialaB.OlsS.et al.Induction of potent neutralizing antibody responses by"/>
 <result pre="neutralizing antibody responses by a designed protein nanoparticle vaccine for" exact="respiratory" post="syncytial virusCell2019176614201431.e1710.1016/j.cell.2019.01.04630849373 203RaiM.DeshmukhS. D.IngleA. P.GuptaI. R.GaldieroM.GaldieroS.Metal nanoparticles: the protective"/>
 <result pre="vaccineScience2020367648085285310.1126/science.aba275432079760 208ShenK.YangY.WangT.et al.Diagnosis, treatment, and prevention of 2019 novel coronavirus" exact="infection" post="in children: expertsâ€™ consensus statementWorld Journal of Pediatrics202010.1007/s12519-020-00343-7 209ChenZ.-M.FuJ."/>
 <result pre="of Pediatrics202010.1007/s12519-020-00343-7 209ChenZ.-M.FuJ. F.ShuQ.et al.Diagnosis and treatment recommendations for pediatric" exact="respiratory" post="infection caused by the 2019 novel coronavirusWorld Journal of"/>
 <result pre="Pediatrics202010.1007/s12519-020-00343-7 209ChenZ.-M.FuJ. F.ShuQ.et al.Diagnosis and treatment recommendations for pediatric respiratory" exact="infection" post="caused by the 2019 novel coronavirusWorld Journal of Pediatrics202010.1007/s12519-020-00345-5"/>
 <result pre="Investigation202013041545154810.1172/JCI13800332167489 211ChenL.XiongJ.BaoL.ShiY.Convalescent plasma as a potential therapy for COVID-19The Lancet" exact="Infectious" post="Diseases202020439840010.1016/S1473-3099(20)30141-932113510 212MaxmenA.More than 80 clinical trials launch to test"/>
 <result pre="supplements ameliorate the adverse effect of HIV-1, malaria, and diarrheal" exact="infections" post="on child growthPediatrics20021091, article e610.1542/peds.109.1.e611773574 216GlasziouP. P.MackerrasD. E.Vitamin A"/>
 <result pre="child growthPediatrics20021091, article e610.1542/peds.109.1.e611773574 216GlasziouP. P.MackerrasD. E.Vitamin A supplementation in" exact="infectious" post="diseases: a meta-analysisBMJ1993306687436637010.1136/bmj.306.6874.3668461682 217HemilÃ¤H.Vitamin C and SARS coronavirusJournal of"/>
 <result pre="and SARS coronavirusJournal of Antimicrobial Chemotherapy20035261049105010.1093/jac/dkh00214613951 218HemilÃ¤H.Vitamin C intake and" exact="susceptibility to" post="pneumoniaThe Pediatric Infectious Disease Journal199716983683710.1097/00006454-199709000-000039306475 219MartineauA. R.JolliffeD. A.HooperR. L.et"/>
 <result pre="of Antimicrobial Chemotherapy20035261049105010.1093/jac/dkh00214613951 218HemilÃ¤H.Vitamin C intake and susceptibility to pneumoniaThe" exact="Pediatric" post="Infectious Disease Journal199716983683710.1097/00006454-199709000-000039306475 219MartineauA. R.JolliffeD. A.HooperR. L.et al.Vitamin D"/>
 <result pre="Antimicrobial Chemotherapy20035261049105010.1093/jac/dkh00214613951 218HemilÃ¤H.Vitamin C intake and susceptibility to pneumoniaThe Pediatric" exact="Infectious" post="Disease Journal199716983683710.1097/00006454-199709000-000039306475 219MartineauA. R.JolliffeD. A.HooperR. L.et al.Vitamin D supplementation"/>
 <result pre="Chemotherapy20035261049105010.1093/jac/dkh00214613951 218HemilÃ¤H.Vitamin C intake and susceptibility to pneumoniaThe Pediatric Infectious" exact="Disease" post="Journal199716983683710.1097/00006454-199709000-000039306475 219MartineauA. R.JolliffeD. A.HooperR. L.et al.Vitamin D supplementation to"/>
 <result pre="Journal199716983683710.1097/00006454-199709000-000039306475 219MartineauA. R.JolliffeD. A.HooperR. L.et al.Vitamin D supplementation to prevent" exact="acute" post="respiratory tract infections: systematic review and meta-analysis of individual"/>
 <result pre="219MartineauA. R.JolliffeD. A.HooperR. L.et al.Vitamin D supplementation to prevent acute" exact="respiratory" post="tract infections: systematic review and meta-analysis of individual participant"/>
 <result pre="viruses in cell culturePLoS Pathogens2010611, article e100117610.1371/journal.ppat.100117621079686 221LassiZ. S.MoinA.BhuttaZ. A.Cochrane" exact="Acute" post="Respiratory Infections GroupZinc supplementation for the prevention of pneumonia"/>
 <result pre="in cell culturePLoS Pathogens2010611, article e100117610.1371/journal.ppat.100117621079686 221LassiZ. S.MoinA.BhuttaZ. A.Cochrane Acute" exact="Respiratory" post="Infections GroupZinc supplementation for the prevention of pneumonia in"/>
 <result pre="cell culturePLoS Pathogens2010611, article e100117610.1371/journal.ppat.100117621079686 221LassiZ. S.MoinA.BhuttaZ. A.Cochrane Acute Respiratory" exact="Infections" post="GroupZinc supplementation for the prevention of pneumonia in children"/>
 <result pre="A.Cochrane Acute Respiratory Infections GroupZinc supplementation for the prevention of" exact="pneumonia" post="in children aged 2 months to 59 monthsCochrane Database"/>
 <result pre="al.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet"/>
 <result pre="pneumonia in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet" exact="Respiratory" post="Medicine20208547548110.1016/S2213-2600(20)30079-532105632 225WuZ.McGooganJ. M.Characteristics of and important lessons from the"/>
 <result pre="Medicine20208547548110.1016/S2213-2600(20)30079-532105632 225WuZ.McGooganJ. M.Characteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in ChinaJAMA2020323131239124210.1001/jama.2020.2648 226KimH.-Y.ShinH. S.ParkH.et al.In vitro"/>
 <result pre="H.ZhouS. P.HeY.Application of integrative medicine protocols on treatment of coronavirus" exact="disease" post="2019Chinese Traditional and Herbal Drugs202051878882 231collab: Publicity Department of"/>
 <result pre="Cell2014111210.15419/psc.v1i1.38 234ChenJ.HuC.ChenL.et al.Clinical study of mesenchymal stem cell treatment for" exact="acute" post="respiratory distress syndrome induced by epidemic influenza A (H7N9)"/>
 <result pre="234ChenJ.HuC.ChenL.et al.Clinical study of mesenchymal stem cell treatment for acute" exact="respiratory" post="distress syndrome induced by epidemic influenza A (H7N9) infection:"/>
 <result pre="study of mesenchymal stem cell treatment for acute respiratory distress" exact="syndrome" post="induced by epidemic influenza A (H7N9) infection: a hint"/>
 <result pre="Special Emphasis on First Insights Concerning SARS2005BirkhÃ¤user BaselBirkhÃ¤user Advances in" exact="Infectious" post="Diseases BAID20121210.1007/3-7643-7339-3_10 241van DoremalenN.BushmakerT.MorrisD. H.et al.Aerosol and surface stability"/>
 <result pre="Emphasis on First Insights Concerning SARS2005BirkhÃ¤user BaselBirkhÃ¤user Advances in Infectious" exact="Diseases" post="BAID20121210.1007/3-7643-7339-3_10 241van DoremalenN.BushmakerT.MorrisD. H.et al.Aerosol and surface stability of"/>
 <result pre="SARS-CoV-2 as compared with SARS-CoV-1New England Journal of Medicine2020382161564156710.1056/NEJMc200497332182409 242SalehiS.AbediA.BalakrishnanS.GholamrezanezhadA.Coronavirus" exact="disease" post="2019 (COVID-19): a systematic review of imaging findings in"/>
 <result pre="mechanism of Lianhua Qingwen Capsules(LHQW) on chemotaxis of macrophages in" exact="acute" post="lung injury (ALI) animal modelChina Journal of Chinese Materia"/>
 <result pre="stimulated RAW 264.7 macrophagesRSC Advances20199168912892510.1039/C9RA00060G 255PengS.HangN.LiuW.et al.Andrographolide sulfonate ameliorates lipopolysaccharide-induced" exact="acute" post="lung injury in mice by down-regulating MAPK and NF-ÎºB"/>
 <result pre="after nucleic amplification. Adapted and copyright with permission (aâ€&quot;c) [70]," exact="American" post="Chemical Society. Figure 6 Lateral flow assays for detecting"/>
 <result pre="transmission electron microscopy characterizations of 2019-nCoV. (a) Cross-sectional noncontrast enhanced" exact="chest" post="CT radiographs of a man's lungs with COVID-19. The"/>
 <result pre="reticulum; N: nucleocapsid protein; M: membrane protein; ERGIC: endoplasmic reticulum-Golgi" exact="intermediate" post="compartment; S: spike glycoprotein. Figure 9 Chemical structure of"/>
 <result pre="Remarks and Ref. Rapid Low cost Sensitive Portable Visual analysis" exact="Antibody" post="â€ƒIgG/IgM-LFA Blood 15â€‰min 92.69% âœ&quot; âœ&quot; âœ&quot; âœ&quot; âœ&quot;"/>
 <result pre="Ref. Rapid Low cost Sensitive Portable Visual analysis Antibody â€ƒIgG/IgM-LFA" exact="Blood" post="15â€‰min 92.69% âœ&quot; âœ&quot; âœ&quot; âœ&quot; âœ&quot; Inapplicable to"/>
 <result pre="âœ&quot; âœ&quot; âœ&quot; âœ&quot; Inapplicable to early-stage detection [243] â€ƒIgG/IgM-AIE-QD" exact="Blood" post="15â€‰min 75% âœ&quot; âœ&quot; âœ&quot; âœ&quot; Inapplicable to early-stage"/>
 <result pre="âœ&quot; âœ&quot; âœ&quot; Inapplicable to early-stage detection [244] â€ƒIgM-colloidal gold-LFA" exact="Blood" post="15â€‰min Not reported âœ&quot; âœ&quot; âœ&quot; âœ&quot; Inapplicable to"/>
 <result pre="âœ&quot; âœ&quot; Inapplicable to early-stage detection [245] â€ƒIgG/IgM-ELISA or LFA" exact="Blood" post="29â€‰min 93.1% âœ&quot; âœ&quot; âœ&quot; âœ&quot; âœ&quot; Inapplicable to"/>
 <result pre="âœ&quot; âœ&quot; âœ&quot; Inapplicable to early-stage detection [246] â€ƒIgG/IgM-colloidal gold-FLA" exact="Blood" post="15-30â€‰min 90% âœ&quot; âœ&quot; âœ&quot; âœ&quot; âœ&quot; Inapplicable to"/>
 <result pre="â€ƒCRISPR-Cas13a/RPA-LFA (SHERLOCK) Synthetic RNA &amp;lt;60â€‰min 10 copies/Î¼L input âœ&quot; âœ&quot;" exact="Simple" post="but requiring clinical validation [60] â€ƒCRISPR-Cas12a/RT-RPA (DETECTR) Synthetic RNA"/>
 <result pre="polymerase amplification; FLA: lateral flow assay; CRISPR: clustered regularly interspaced" exact="short" post="palindromic repeats; DETECTR: DNA endonuclease-targeted CRISPR trans reporter. Table"/>
 <result pre="for coronaviruses In vitro antiviral activities against 2019-nCoV in human" exact="lung cancer" post="cells [113] Not known None Lopinavir-ritonavir Viral protease Used"/>
 <result pre="coronaviruses In vitro antiviral activities against 2019-nCoV in human lung" exact="cancer" post="cells [113] Not known None Lopinavir-ritonavir Viral protease Used"/>
 <result pre="in human lung cancer cells [113] Not known None Lopinavir-ritonavir" exact="Viral" post="protease Used in combination with ribavirin for SARS and"/>
 <result pre="However, found to be ineffective based on preliminary findings Darunavir" exact="Viral" post="protease Antiretroviral drug; not yet tested for coronaviruses N/A"/>
 <result pre="ingredients (common names) Active ingredients Precaution Suspected cases â€ƒFatigue, gastrointestinal" exact="discomfort" post="Huo Xiang Zheng Qi Capsule (è—¿é¦™æ­£æ°&quot;èƒ¶å›Š) Patchouli, Indian buead,"/>
 <result pre="rhizome, magnolia bark, pinellia rhizome, licorice N/A May cause an" exact="autoimmune" post="response. Allergic individuals are prohibited from the treatment. Patients"/>
 <result pre="bark, pinellia rhizome, licorice N/A May cause an autoimmune response." exact="Allergic" post="individuals are prohibited from the treatment. Patients with diseases,"/>
 <result pre="the treatment. Patients with diseases, i.e., cardiac diseases, liver diseases," exact="kidney diseases," post="hypertension, and diabetes, and pregnant women should speak to"/>
 <result pre="patchouli, rhubarb, arctic root, mint, licorice N/A May cause an" exact="autoimmune" post="response. Not suitable for people with a cold. Not"/>
 <result pre="for people with a cold. Not suitable for long-term use." exact="Allergic" post="individuals are prohibited from the treatment. Patients with diseases,"/>
 <result pre="the treatment. Patients with diseases, i.e., cardiac diseases, liver diseases," exact="kidney diseases," post="hypertension, and diabetes, and pregnant women should speak to"/>
 <result pre="patrinia, verbena leaf, reed root, licorice N/A May cause an" exact="autoimmune" post="response, i.e., nausea. Allergic individuals and individuals with allergic"/>
 <result pre="root, licorice N/A May cause an autoimmune response, i.e., nausea." exact="Allergic" post="individuals and individuals with allergic constitution are prohibited from"/>
 <result pre="borneol, cape jasmine fruit, turmeric tuber N/A May cause an" exact="autoimmune" post="response, i.e., skin rash. Pregnant women are prohibited from"/>
 <result pre="root, Chinese angelica root Hydroxysafflor yellow A May cause an" exact="autoimmune" post="response, i.e., itchiness. Pregnant women are prohibited from the"/>
 <result pre="Wormwood, honeysuckle flower, cape jasmine fruit N/A May cause an" exact="autoimmune" post="response, i.e., dizziness, chest tightness, thirstiness, diarrhea, nausea, vomit,"/>
 <result pre="jasmine fruit N/A May cause an autoimmune response, i.e., dizziness," exact="chest" post="tightness, thirstiness, diarrhea, nausea, vomit, skin rash, and itchiness."/>
 <result pre="chest tightness, thirstiness, diarrhea, nausea, vomit, skin rash, and itchiness." exact="Allergic" post="individuals are prohibited from the treatment Tan Re Qing"/>
 <result pre="bile, goat horn, honeysuckle flower, forsythia N/A May cause an" exact="autoimmune" post="response, i.e., dizziness, nausea, vomit, itchiness, and skin rash"/>
 <result pre="Injection (å�‚é™&quot;æ³¨å°&quot;æ¶²) Red ginseng, Chinese aconite N/A May cause an" exact="autoimmune" post="response, i.e., tachycardia, skin rash, dizziness, headache, hiccup, tremor,"/>
 <result pre="i.e., tachycardia, skin rash, dizziness, headache, hiccup, tremor, dyspnea, nausea," exact="visual" post="abnormality, abnormality in liver function, and urinary retention. Newborns,"/>
 <result pre="(ç&quot;Ÿè&quot;‰æ³¨å°&quot;æ¶²) Red ginseng, Ophiopogon, magnolia berry N/A May cause an" exact="autoimmune" post="response, i.e., anaphylactic shock. Newborns, pregnant women, allergic individuals,"/>
 <result pre="Shen Mai Injection (å�‚éº¦æ³¨å°&quot;æ¶²) Red ginseng, Ophiopogon N/A May cause" exact="autoimmune" post="response and adverse effect on treated patients, i.e., anaphylactic"/>
 <result pre="root, cape jasmine fruit, turmeric tuber, borneol N/A May cause" exact="autoimmune" post="responses, i.e., hypothermia. Prescription guidance is unclear N/A: not"/>
 <result pre="Vaccine type/platform Developer Vaccine name Vaccine type/platform Developer Ad5-nCoVâˆ—âˆ— DNA/adenovirus" exact="type 5" post="vector CanSino Biological Inc., Beijing Institute of Biotechnology Vaxil"/>
 <result pre="Biological Inc., Beijing Institute of Biotechnology Vaxil Bio COVID-19 vaccine" exact="Protein" post="subunit/signal peptide combinations Vaxil Bio INO-4800 DNA/DNA plasmid, electroporation"/>
 <result pre="Vaxil Bio INO-4800 DNA/DNA plasmid, electroporation device Inovio Pharmaceuticals COVID-19S-Trimer" exact="Protein" post="subunit/pandemic adjuvant system Clover Biopharmaceuticals Inc./GSK N/Aâˆ— DNA/S gene"/>
 <result pre="Clover Biopharmaceuticals Inc./GSK N/Aâˆ— DNA/S gene Takis/Applied DNA Sciences/Evvivax N/A" exact="Protein" post="subunit/S protein AJ Vaccine N/A DNA plasmid Zydus Cadila"/>
 <result pre="subunit/S protein AJ Vaccine N/A DNA plasmid Zydus Cadila N/A" exact="Protein" post="subunit/li-Key peptide Generex/EpiVax N/A Ad26/MVA boost Janssen Pharmaceutical Companies"/>
 <result pre="subunit/li-Key peptide Generex/EpiVax N/A Ad26/MVA boost Janssen Pharmaceutical Companies N/A" exact="Protein" post="subunit/S protein EpiVax/Univ. of Georgia GV-MVA-VLP/vaccine DNA/nonreplicating viral vector"/>
 <result pre="Companies N/A Protein subunit/S protein EpiVax/Univ. of Georgia GV-MVA-VLP/vaccine DNA/nonreplicating" exact="viral" post="vector GeoVax/BravoVax Protein subunit/S protein (baculovirus production) Sanofi Pasteur"/>
 <result pre="subunit/S protein EpiVax/Univ. of Georgia GV-MVA-VLP/vaccine DNA/nonreplicating viral vector GeoVax/BravoVax" exact="Protein" post="subunit/S protein (baculovirus production) Sanofi Pasteur ChAdOx-nCoV-19âˆ— DNA/nonreplicating viral"/>
 <result pre="GeoVax/BravoVax Protein subunit/S protein (baculovirus production) Sanofi Pasteur ChAdOx-nCoV-19âˆ— DNA/nonreplicating" exact="viral" post="vector University of Oxford N/Aâˆ— Protein subunit/Full-length proteinMatrix-MTM adjuvant"/>
 <result pre="Sanofi Pasteur ChAdOx-nCoV-19âˆ— DNA/nonreplicating viral vector University of Oxford N/Aâˆ—" exact="Protein" post="subunit/Full-length proteinMatrix-MTM adjuvant Novavax N/A DNA/nonreplicating viral vector, NasoVAX-S"/>
 <result pre="of Oxford N/Aâˆ— Protein subunit/Full-length proteinMatrix-MTM adjuvant Novavax N/A DNA/nonreplicating" exact="viral" post="vector, NasoVAX-S gene Altimmune Heat's gp96 based vaccine for"/>
 <result pre="vector, NasoVAX-S gene Altimmune Heat's gp96 based vaccine for COVID-19" exact="Protein" post="subunit/Heat's gp96 backbone to express antigen of COVID-19 Heat"/>
 <result pre="express antigen of COVID-19 Heat Biologics/Univ. of Miami N/A DNA/nonreplicating" exact="viral" post="vector (Ad5 S) Greffex N/A Protein subunit/molecular clamp stabilized"/>
 <result pre="of Miami N/A DNA/nonreplicating viral vector (Ad5 S) Greffex N/A" exact="Protein" post="subunit/molecular clamp stabilized spike protein University of Queensland/GSK N/A"/>
 <result pre="subunit/molecular clamp stabilized spike protein University of Queensland/GSK N/A DNA/nonreplicating" exact="viral" post="vector (VAAST); oral vaccine platform Vaxart, Inc. N/A Protein"/>
 <result pre="DNA/nonreplicating viral vector (VAAST); oral vaccine platform Vaxart, Inc. N/A" exact="Protein" post="subunit/molecular clamp stabilized spike protein University of Queensland/GSK N/A"/>
 <result pre="spike protein University of Queensland/GSK N/A DNA vaccine/measles vector (replicating" exact="viral" post="vector) Vaxart, Inc. N/A Protein subunit/S1 or RBD protein"/>
 <result pre="N/A DNA vaccine/measles vector (replicating viral vector) Vaxart, Inc. N/A" exact="Protein" post="subunit/S1 or RBD protein Baylor College of Medicine N/A"/>
 <result pre="vector Institute Pasteur/Themis/Univ. of Pittsburg Center for Vaccine Research N/A" exact="Protein" post="subunit/plant-based coronavirus iBio/CC-Pharming TNX-1800/COVID-19 DNA vaccine/horsepox vaccine platform-S gene"/>
 <result pre="TNX-1800/COVID-19 DNA vaccine/horsepox vaccine platform-S gene Tonix Pharma/Southern Research N/Aâˆ—" exact="Protein" post="subunit/protein VIDO-InterVac, University of Saskatchewan mRNA-1273âˆ—âˆ— mRNA/novel lipid nanoparticle"/>
 <result pre="VIDO-InterVac, University of Saskatchewan mRNA-1273âˆ—âˆ— mRNA/novel lipid nanoparticle Moderna/NIAID N/A" exact="Protein" post="subunit/protein University of Saskatchewan N/A mRNA vaccine/VLP-cocktail (S, M,"/>
 <result pre="N/A mRNA CureVac N/A Unknown MIGAL Galilee Research Institute N/A" exact="Protein" post="subunit/Drosophila S2 insect cell expression system VLPs ExpreS2ion N/A"/>
 <result pre="membrane Phase 4 trials for COVID-19 [122â€&quot;124] â€ƒChloroquine and derivatives" exact="Malaria" post="Inhibition of lysosomal activity and signaling pathway in virus"/>
 <result pre="the treatment of COVID-19 [159, 160] â€ƒDarunavir HIV Inhibition of" exact="viral" post="maturation pathways Phase 2-3 trials for the treatment of"/>
 <result pre="viral maturation pathways Phase 2-3 trials for the treatment of" exact="pneumonia" post="caused by COVID-19 [164] â€ƒCamostat mesylate Pancreatic inflammation Inhibition"/>
 <result pre="caused by COVID-19 [164] â€ƒCamostat mesylate Pancreatic inflammation Inhibition of" exact="viral" post="entry into host cells Preclinical [113, 151, 152] â€ƒRemdesivir"/>
 <result pre="host cells Preclinical [113, 151, 152] â€ƒRemdesivir Ebola (proposed) Inhibits" exact="viral" post="RNA polymerase Phase 3 trials for the treatment of"/>
 <result pre="treatment of COVID-19 [138, 179â€&quot;182] â€ƒRibavirin HCV, RSV Inhibition of" exact="viral" post="RNA replication &amp;amp; increased mutation in viral RNA Phase"/>
 <result pre="RSV Inhibition of viral RNA replication &amp;amp; increased mutation in" exact="viral" post="RNA Phase 2 trials for the treatment of COVID-19"/>
 <result pre="[168â€&quot;172] Biologics â€‰ â€‰ â€‰ â€‰ â€‰ â€ƒINF-Î± HCV, HCL," exact="melanoma" post="Invoking interferon response through exogenous interferons Multiple randomized trials"/>
 <result pre="â€ƒINF-Î± HCV, HCL, melanoma Invoking interferon response through exogenous interferons" exact="Multiple" post="randomized trials for COVID-19 patients [208, 209] â€ƒConvalescent plasma"/>
 <result pre="209] â€ƒConvalescent plasma Influenza, Ebola, SARS, MERS Suppression of viremia" exact="Multiple" post="randomized trials for COVID-19 [212, 213] â€ƒHuman monoclonal antibodies"/>
 <result pre="[214] â€ƒmRNA-1273, Ad5-nCoV Nil Eliciting immune response via host cell-expressed" exact="viral" post="protein Phase 1 clinical trials for prevention of COVID-19"/>
 <result pre="viral protein Phase 1 clinical trials for prevention of COVID-19" exact="infection" post="[237, 238] â€ƒB &amp;amp; T cell epitopes SARS-CoV Invoke"/>
 <result pre="SARS-CoV Invoke immune targeting of these epitopes Preclinical [251] â€ƒMSC" exact="Heart" post="disease, Parkinson's disease, lung cancer, type 1 diabetes, stroke"/>
 <result pre="immune targeting of these epitopes Preclinical [251] â€ƒMSC Heart disease," exact="Parkinson's disease," post="lung cancer, type 1 diabetes, stroke Promotes endothelial repair"/>
 <result pre="of these epitopes Preclinical [251] â€ƒMSC Heart disease, Parkinson's disease," exact="lung cancer," post="type 1 diabetes, stroke Promotes endothelial repair and reduce"/>
 <result pre="epitopes Preclinical [251] â€ƒMSC Heart disease, Parkinson's disease, lung cancer," exact="type 1" post="diabetes, stroke Promotes endothelial repair and reduce inflammation through"/>
 <result pre="â€ƒMSC Heart disease, Parkinson's disease, lung cancer, type 1 diabetes," exact="stroke" post="Promotes endothelial repair and reduce inflammation through secretion of"/>
 <result pre="Wen Capsule Influenza Downregulates MCP-1 which decreases monocytes chemotaxis to" exact="infection" post="foci Phase 4 trials for the treatment of COVID-19"/>
 <result pre="for the treatment of COVID-19 [25, 256] â€ƒShen Fu Injection" exact="Congestive" post="heart failure, ischemic stroke Affect various immune signaling pathways"/>
 <result pre="the treatment of COVID-19 [25, 256] â€ƒShen Fu Injection Congestive" exact="heart" post="failure, ischemic stroke Affect various immune signaling pathways to"/>
 <result pre="COVID-19 [25, 256] â€ƒShen Fu Injection Congestive heart failure, ischemic" exact="stroke" post="Affect various immune signaling pathways to have a protective"/>
 <result pre="treatment of COVID-19 [25, 257] Abbreviations: 3CLpro: 3C-like protease; COPD:" exact="chronic" post="obstructive pulmonary disease; HCL: hairy cell leukemia; HCV: hepatitis"/>
 <result pre="COVID-19 [25, 257] Abbreviations: 3CLpro: 3C-like protease; COPD: chronic obstructive" exact="pulmonary" post="disease; HCL: hairy cell leukemia; HCV: hepatitis C virus;"/>
 <result pre="Abbreviations: 3CLpro: 3C-like protease; COPD: chronic obstructive pulmonary disease; HCL:" exact="hairy cell leukemia;" post="HCV: hepatitis C virus; HFMD: hand, foot, and mouth"/>
 <result pre="COPD: chronic obstructive pulmonary disease; HCL: hairy cell leukemia; HCV:" exact="hepatitis C" post="virus; HFMD: hand, foot, and mouth disease; HIV: human"/>
 <result pre="disease; HCL: hairy cell leukemia; HCV: hepatitis C virus; HFMD:" exact="hand, foot, and mouth disease;" post="HIV: human immunodeficiency virus; IL-6: interleukin 6; INF-Î±: interferon-alpha;"/>
 <result pre="C virus; HFMD: hand, foot, and mouth disease; HIV: human" exact="immunodeficiency" post="virus; IL-6: interleukin 6; INF-Î±: interferon-alpha; MAPK: mitogen-activated protein"/>
 <result pre="IL-6: interleukin 6; INF-Î±: interferon-alpha; MAPK: mitogen-activated protein kinase; MCP-1:" exact="monocyte" post="chemoattractant protein-1; MERS-CoV: Middle East respiratory syndrome-coronavirus; MSC: mesenchymal"/>
 <result pre="mitogen-activated protein kinase; MCP-1: monocyte chemoattractant protein-1; MERS-CoV: Middle East" exact="respiratory" post="syndrome-coronavirus; MSC: mesenchymal stem cell; NF-ÎºB: nuclear factor kappa-light-chain-enhancer"/>
 <result pre="B cells; RdRp: RNA-dependent RNA polymerase; RNA: ribonucleic acid; RSV:" exact="respiratory" post="syncytial virus; SARS-CoV: severe acute respiratory syndrome-coronavirus; Th17: T"/>
 <result pre="polymerase; RNA: ribonucleic acid; RSV: respiratory syncytial virus; SARS-CoV: severe" exact="acute" post="respiratory syndrome-coronavirus; Th17: T helper 17; TNF-Î±: tumor necrosis"/>
 <result pre="RNA: ribonucleic acid; RSV: respiratory syncytial virus; SARS-CoV: severe acute" exact="respiratory" post="syndrome-coronavirus; Th17: T helper 17; TNF-Î±: tumor necrosis factor-alpha;"/>
 <result pre="SARS-CoV: severe acute respiratory syndrome-coronavirus; Th17: T helper 17; TNF-Î±:" exact="tumor" post="necrosis factor-alpha; URTI: upper respiratory tract infection."/>
 <result pre="syndrome-coronavirus; Th17: T helper 17; TNF-Î±: tumor necrosis factor-alpha; URTI:" exact="upper respiratory tract infection." post=""/>
 <result pre="Th17: T helper 17; TNF-Î±: tumor necrosis factor-alpha; URTI: upper" exact="respiratory" post="tract infection."/>
</results>
